Tan et al., 2019 - Google Patents
Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort studyTan et al., 2019
View HTML- Document ID
- 12487345809718312197
- Author
- Tan I
- Stinchcombe T
- Ready N
- Crawford J
- Datto M
- Nagy R
- Lanman R
- Gu L
- Clarke J
- Publication year
- Publication venue
- Translational Lung Cancer Research
External Links
Snippet
Background Data describing therapeutic outcomes in patients with non-small cell lung cancers (NSCLC) with BRAF mutations remains limited. Methods We conducted a retrospective cohort study of 31 patients with metastatic NSCLC treated at Duke University …
- 230000035772 mutation 0 title abstract description 104
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pakkala et al. | Personalized therapy for lung cancer: striking a moving target | |
Okamura et al. | ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy | |
Raghav et al. | Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer | |
Aguilar et al. | Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression | |
Marcoux et al. | EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes | |
Reck | Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer | |
Thompson et al. | Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy | |
Petty et al. | Gefitinib and EGFR gene copy number aberrations in esophageal cancer | |
Tan et al. | Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study | |
Uruga et al. | Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases | |
Majewski et al. | PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2–targeted therapies in breast cancer | |
Kato et al. | Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies | |
Roberts et al. | KRAS mutation: should we test for it, and does it matter? | |
Laurie et al. | Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non–small-cell lung cancer | |
Lim et al. | Pembrolizumab for the treatment of non-small cell lung cancer | |
Catalanotti et al. | PTEN loss-of-function alterations are associated with intrinsic resistance to BRAF inhibitors in metastatic melanoma | |
Afghahi et al. | Targeted therapy for cancer in the genomic era | |
La Salvia et al. | HER2-targeted therapy: an emerging strategy in advanced colorectal cancer | |
Chu et al. | Population-based screening for BRAF V600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis | |
Amanam et al. | Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival | |
Ohba et al. | Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab | |
Mazza et al. | Treating EGFR mutation resistance in non-small cell lung cancer–role of osimertinib | |
Baldacci et al. | Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors | |
Yang et al. | Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations | |
Bruera et al. | KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy |